TScan Therapeutics Reorganizes to Focus on In Vivo TCR-T Cell Therapy for Solid Tumors
Waltham, Mass., September 2, 2026 TScan Therapeutics, Inc. announced a strategic reorganization to prioritize its in vivo-engineered TCR-T cell...
MAGE-A4
Advertisement
Zelluna Doses First Patient With TCR-NK Therapy
OSLO, Norway, July 13, 2026 Zelluna announced that the first patient has been dosed in the ZIMA-101 Phase 1...
US WorldMeds Secures Full FDA Approval for TECELRA
LOUISVILLE, Kentucky, June 22, 2026 US WorldMeds has announced that the U.S. Food and Drug Administration (FDA) has granted...
Zelluna ASA Activates First Clinical Site for ZIMA-101 Phase 1 Solid Cancer Trial
OSLO, Norway, May 6, 2026 Zelluna ASA announced the activation of the first clinical site for its ZIMA-101 Phase...
Advertisement
